1. Progression After Cancer Immunotherapy in Advanced NSCLC

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Patterns of Progression

4. Considerations for Management of Progressive Disease

5. Patient Case #1

6. Second-Line Treatment Options

7. The Treatment Option of Clinical Trials

8. Patient Case #1 (cont)

9. Patient Case #2

10. Third-Line Treatment Options

11. Tips for Remaining Current With Data

12. Concluding Remarks

13. Abbreviations